Ifm_05-may 2022 Apr 2026

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI IFM_05-May 2022

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. The study demonstrated a clear overall survival benefit

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations